PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.

Br J Cancer · 2007 · PMC2360431 · PMID 17940504

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

If we pool our data with those of these three studies ( Moroni et al , 2005 ; Lievre et al , 2006; Di Fiore et al , 2007 ), the difference between K-Ras mutated and K-Ras wild-type sequence patients as regards to cetuximab treatment is highly significant, indicating that the assessment of K-Ras mutations in mCRC plays a fundamental role in predicting cetuximab efficacy.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.